Clinical Trials Directory

Trials / Unknown

UnknownNCT04655209

Augmenting the Effects of Mirror Therapy for Stroke Rehabilitation by tDCS

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
75 (estimated)
Sponsor
Chang Gung Memorial Hospital · Academic / Other
Sex
All
Age
45 Years – 85 Years
Healthy volunteers
Not accepted

Summary

This project is to evaluate and compare the impact of tDCS stimulation location on augmenting MT effects.

Detailed description

Mirror therapy (MT) has emerged as an effective treatment approach for stroke rehabilitation. To augment the effects of MT, one appealing approach is to combine MT with transcranial direct current stimulation (tDCS) to promote neuroplasticity. However, it remains undetermined as to how tDCS may be effectively and efficiently applied in conjunction with MT. The long term goal of this project will be to identify the optimal combination approach of MT and tDCS to enhance recovery after stroke. The stimulation timing and location of tDCS in relation to MT will be varied, and the scientific evidence will be built upon by the evaluation of comprehensive outcome measures. This project will also investigate the possible electroencephalography (EEG) physiological and motor control mechanisms, and study predictors of treatment success to identify the appropriate patient population for the hybrid regimen. Specifically, the first aim of this project is to evaluate and compare the impact of tDCS stimulation location on augmenting MT effects. The tDCS will be applied either before or concurrently with MT, and will be applied either over primary motor cortex (M1) or premotor cortex (PMC). Outcome measures will include behavioral performances selected based on the International Classification of Functioning, Disability and Health (ICF) framework, EEG physiological measures, and kinematic control of upper extremity (UE) movements. All the outcome measures will be assessed before and immediately after the intervention, and only behavioral performances will be evaluated at 3- and 6-month follow-up. Investigators hypothesize that immediately after intervention, the participants who receive MT combined with tDCS will demonstrate greater improvements in the outcomes than those who receive MT with sham tDCS. Investigators also hypothesize that the stimulation location of tDCS will induce differential therapeutic effects on the outcome measures. The second aim of this study is to examine the retention performance of the behavioral outcomes at 3-and 6-month follow-up. Investigators hypothesize that the beneficial effects of the hybrid therapy will be retained 3 and 6 months post intervention. The third aim of this study is to perform subsequent analysis of exploring whether patients with primary motor cortex involved will respond to various types of treatment differently from those without primary motor cortex involved. The fourth aim of the study is to identify the characteristics of responders for the hybrid therapy. The possible predictors of post treatment changes in behavioral (the aspects of activities and participation), EEG physiological, and kinematic measures will be determined. Investigators hypothesize that the behavioral (the aspect of motor impairment), the EEG physiological and the kinematic measures will be good predictors for the treatment outcomes.

Conditions

Interventions

TypeNameDescription
BEHAVIORALapply a-tDCS on the ipsilesional M1 followed by MT (M1-Seq)The participants in the M1-Seq group will first receive a-tDCS over ipsi-lesional M1 without any active arm practice for 20 minutes. For the next 20 minutes, the participants will start the MT, while the electrodes will be remained on the scalp with the stimulator off (sham tDCS condition). Then the electrodes will be removed, and the participants will receive additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.
BEHAVIORALapply a-tDCS on the ipsilesional PMC followed by MT (PMC-Seq)The procedures for the PMC-Seq group will be the same as the M1-Seq, except that a-tDCS will be applied on ipsilesional PMC but not M1.
BEHAVIORALMT only with sham tDCS (MT)For the MT group, the procedure will be the same as the other groups except that sham tDCS will be used for the first 40 minutes.

Timeline

Start date
2017-07-04
Primary completion
2021-12-01
Completion
2021-12-01
First posted
2020-12-07
Last updated
2021-01-11

Locations

2 sites across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT04655209. Inclusion in this directory is not an endorsement.